^
CANCER:

Penile Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Penile Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Penile Cancer
capecitabine
Sensitive
:
A2
No biomarker
Penile Cancer
cetuximab
Sensitive
:
A2
No biomarker
Penile Cancer
cisplatin
Sensitive
:
A2
No biomarker
Penile Cancer
5-fluorouracil + mitomycin
Sensitive
:
A2
No biomarker
Penile Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Penile Cancer
cisplatin + irinotecan
Sensitive
:
A2
No biomarker
Penile Cancer
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Penile Cancer
imiquimod
Sensitive
:
A2
No biomarker
Penile Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Penile Cancer
TIP
Sensitive
:
A2
MSI-H/dMMR
Penile Cancer
pembrolizumab
Sensitive
:
A2
TMB-H
Penile Cancer
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Penile Cancer
pembrolizumab
Sensitive
:
C1
TMB-H + PD-L1 expression + MSI-L/dMMR
Penile Cancer
nivolumab + ipilimumab
Sensitive
:
C4
TMB-H + PD-L1 expression
Penile Cancer
toripalimab
Sensitive
:
C4
CDKN2A mutation
Penile Cancer
nivolumab
Sensitive
:
C4